With the new BD MAX MDR TB test, clinicians can simultaneously detect bacteria that cause TB and determine if the bacteria contain mutations associated with resistance to two important first-line drugs-Isoniazid (INH) and Rifampicin (RIF), respectively
Redcliffe Labs launches BD MAX MDR TB test, which can detect multidrug-resistant tuberculosis (MDR-TB) in a single test, enabling clinicians to quickly test for Tuberculosis (TB) and multidrug resistance as a first-line test. The test, conducted at Redcliffe Labs in Noida, is the first of its kind in India and will significantly enhance the information available to direct the optimal treatment for patients.
With the new BD MAX MDR TB test, clinicians can simultaneously detect bacteria that cause TB and determine if the bacteria contain mutations associated with resistance to two important first-line drugs-Isoniazid (INH) and Rifampicin (RIF), respectively. This makes TB detection quick and easy and eliminates the need for separate tests for drug resistance against Rifampicin and Isoniazid.
Prof. Ashok Rattan, Chairman of Medical Committee & Quality, Redcliffe Labs said, “This new launch is a game-changer for TB detection in India. Antimicrobial resistance has made TB identification more complex, and the BD MAX MDR-TB panel provides a comprehensive solution that is quick, efficient, and accurate.”
“Although TB can affect any part of the body, pulmonary TB is the most typical manifestation of the disease, transmitted through the respiratory route. Cough, low-grade fever, night sweats, and weight loss are the four cardinal symptoms of TB. Anyone experiencing these for more than two weeks should seek medical attention”, he added.